Paradigm Biocapital Advisors LP Tarsus Pharmaceuticals, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.14 Billion
- Q2 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 2,976,099 shares of TARS stock, worth $210 Million. This represents 5.63% of its overall portfolio holdings.
Number of Shares
2,976,099
Previous 2,610,197
14.02%
Holding current value
$210 Million
Previous $134 Million
10.09%
% of portfolio
5.63%
Previous 6.87%
Shares
7 transactions
Others Institutions Holding TARS
# of Institutions
216Shares Held
46.9MCall Options Held
7.8KPut Options Held
0-
Black Rock Inc. New York, NY3.27MShares$230 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY3.11MShares$219 Million1.94% of portfolio
-
Jennison Associates LLC2.6MShares$184 Million0.09% of portfolio
-
Tang Capital Management LLC San Diego, CA2.45MShares$173 Million5.96% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.3MShares$162 Million0.0% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $1.88B
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...